Novavax Inc (NVAX) — closed signal from May 2, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 31, 2026.
Predicted vs. what happened
NVAX price · publication thesis → realized outcomesplit-adjusted
$7.50 – $8.25Entry zone — fair-value band
$8.04Published — price the day we called it
$9.49Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$7.32Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 4 days.
Peak price
$11.61
peak on May 27, 2026 — not a realized returnPeak gain
+44.3%
peak, from the publication priceWindow close
$7.32
end-of-window price, context onlyDays to target
4
Window
May 2, 2026 – July 31, 2026
The thesis — published May 2, 2026
Predicted growth
+18%
over the measurement windowTarget price
$9.49
the price the thesis aimed forEntry zone
$7.50 – $8.25
the fair-value band we waited forPrice at publication
$8.04
published May 2, 2026Confidence
64%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novavax could be a big winner if partnerships and future vaccine results pay off, but the path is risky. The company is shifting toward licensing and royalty deals with big partners while waiting for combo-vaccine data. Strong cash and many short positions could make moves larger, but weak guidance and volatile results make the near-term setup speculative.
Primary drivers
- Licensing deals reduce the burden of selling vaccines in-house
- Royalty-style revenue can make future cash flow easier to predict
- Healthy cash reserves give the company more strategic options
- Lots of shorted shares can make price moves larger around news
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.